JP2020525416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525416A5 JP2020525416A5 JP2019569289A JP2019569289A JP2020525416A5 JP 2020525416 A5 JP2020525416 A5 JP 2020525416A5 JP 2019569289 A JP2019569289 A JP 2019569289A JP 2019569289 A JP2019569289 A JP 2019569289A JP 2020525416 A5 JP2020525416 A5 JP 2020525416A5
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- ophthalmic
- eye
- disease
- coagulable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 44
- 229920000669 heparin Polymers 0.000 claims 43
- 229960002897 heparin Drugs 0.000 claims 40
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 238000002360 preparation method Methods 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 6
- 239000003055 low molecular weight heparin Substances 0.000 claims 6
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 5
- 208000023715 Ocular surface disease Diseases 0.000 claims 5
- 239000002628 heparin derivative Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 241001111421 Pannus Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001112 coagulating effect Effects 0.000 claims 3
- 201000000159 corneal neovascularization Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 210000000744 eyelid Anatomy 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- -1 heparin oligosaccharide Chemical class 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 229920001542 oligosaccharide Polymers 0.000 claims 3
- 239000008217 ophthalmic excipient Substances 0.000 claims 3
- 230000002980 postoperative effect Effects 0.000 claims 3
- 238000004904 shortening Methods 0.000 claims 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010042736 Symblepharon Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000002510 keratinocyte Anatomy 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 210000004175 meibomian gland Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010069497 Floppy eyelid syndrome Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000601647 Homo sapiens Paired box protein Pax-6 Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010052143 Ocular discomfort Diseases 0.000 claims 1
- 102100037506 Paired box protein Pax-6 Human genes 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003780 keratinization Effects 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000000508 neurotrophic effect Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762526891P | 2017-06-29 | 2017-06-29 | |
| US62/526,891 | 2017-06-29 | ||
| US201762575508P | 2017-10-22 | 2017-10-22 | |
| US62/575,508 | 2017-10-22 | ||
| PCT/US2018/020455 WO2019005222A1 (en) | 2017-06-29 | 2018-03-01 | TREATMENT AND DIAGNOSIS OF OCULAR SURFACE DISORDERS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525416A JP2020525416A (ja) | 2020-08-27 |
| JP2020525416A5 true JP2020525416A5 (https=) | 2021-05-20 |
Family
ID=64734716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569289A Pending JP2020525416A (ja) | 2017-06-29 | 2018-03-01 | 眼表面障害の治療及び診断 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11058713B2 (https=) |
| EP (1) | EP3644966A4 (https=) |
| JP (1) | JP2020525416A (https=) |
| WO (1) | WO2019005222A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230091716A1 (en) * | 2020-02-12 | 2023-03-23 | Glia, Llc | Progesterone Combinations |
| DE102020104540A1 (de) * | 2020-02-20 | 2021-08-26 | Carl Zeiss Meditec Ag | Ophthalmologische Zusammensetzung und Detektionsvorrichtung für ein medizinisches Gerät |
| US20220160668A1 (en) | 2020-11-23 | 2022-05-26 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
| KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
| JP7514033B2 (ja) * | 2022-08-23 | 2024-07-10 | 株式会社エムズサイエンス | 角膜障害治療剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2207049A (en) * | 1987-07-15 | 1989-01-25 | Steven B Siepser | Heparin formulation for use in eye surgery |
| US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
| JP4682495B2 (ja) * | 1999-09-06 | 2011-05-11 | 小野薬品工業株式会社 | 眼疾患の予防、治療剤 |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| CN1394610A (zh) * | 2002-07-12 | 2003-02-05 | 黄建林 | 肝素钙眼药水 |
| CN1459291A (zh) * | 2003-05-28 | 2003-12-03 | 凌沛学 | 含低分子肝素的滴眼液及其制备方法 |
| EP1720555A1 (en) * | 2004-02-26 | 2006-11-15 | Advanced Ocular Systems Limited | Tetracycline derivatives for the treatment of ocular pathologies |
| GB0404693D0 (en) * | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US8372814B2 (en) * | 2004-06-07 | 2013-02-12 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
| US20060122152A1 (en) * | 2004-12-03 | 2006-06-08 | Peyman Gholam A | Heparin for the treatment of ocular pathologies |
| US20060276440A1 (en) * | 2005-01-03 | 2006-12-07 | An Wenqian F | Treatment of inflammatory disorders |
| US20080274104A1 (en) * | 2005-02-10 | 2008-11-06 | Arlinghaus Ralph B | Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| US20090253661A1 (en) * | 2008-04-04 | 2009-10-08 | Gholam A. Peyman | Ocular agents |
| US9867871B2 (en) * | 2011-12-12 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| EP2794550B1 (en) * | 2011-12-23 | 2019-02-20 | University of Western Sydney | Ophthalmic formulation |
| RU2535115C1 (ru) * | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
| EP3094651B1 (en) * | 2014-01-14 | 2020-03-11 | Kymab Limited | Anti-light antibodies |
| JP2018524067A (ja) * | 2015-06-11 | 2018-08-30 | アットウィル メディカル ソルーションズ インコーポレイテッド | アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法 |
| US20190093165A1 (en) * | 2016-02-29 | 2019-03-28 | Santen Sas | Gene signature for the prognosis of dry eye disease |
-
2018
- 2018-03-01 JP JP2019569289A patent/JP2020525416A/ja active Pending
- 2018-03-01 US US15/909,239 patent/US11058713B2/en active Active
- 2018-03-01 WO PCT/US2018/020455 patent/WO2019005222A1/en not_active Ceased
- 2018-03-01 EP EP18824265.5A patent/EP3644966A4/en not_active Withdrawn
-
2021
- 2021-06-28 US US17/361,310 patent/US20210322457A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525416A5 (https=) | ||
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| AU2019232153B2 (en) | Ophthalmic formulation | |
| JP7547411B2 (ja) | 局所用シクロスポリン含有製剤およびその使用 | |
| US20210205217A1 (en) | Microemulsion compositions | |
| US20120004158A1 (en) | Quaternised Ammonium Cyclodextrin Compounds | |
| JP2013513586A (ja) | ドライアイ症候群の治療のための医薬組成物 | |
| KR101778004B1 (ko) | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 | |
| JP2017507158A5 (https=) | ||
| Bernatchez et al. | Use of hyaluronic acid in ocular therapy | |
| CN103209683B (zh) | 角鲨胺的眼用制剂 | |
| Brjesky et al. | Glaucoma and the dry eye syndrome | |
| CN1302812C (zh) | 含海藻糖和玻璃酸的眼部用药传递系统及其制备方法 | |
| JP6931493B2 (ja) | 緑内障治療用点眼組成物 | |
| JP2026004313A (ja) | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤 | |
| WO2025261323A1 (zh) | 一种依维莫司眼局部给药制剂 | |
| DK3229780T3 (en) | Ophthalmic composition for use in the treatment of dry eye syndrome | |
| CN100522147C (zh) | 5,6,7-三羟基庚酸及其类似物在制备治疗干眼病和眼色素层炎药物中的应用 | |
| US10905695B2 (en) | Ophthalmic composition for lowering intraocular pressure | |
| US20180221417A1 (en) | Treatment of dry eye using amnion released factors | |
| KR102790252B1 (ko) | 각막 손상 또는 안구건조증 예방 또는 치료용 조성물 | |
| CN118995345B (zh) | 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法 | |
| JPWO2006098292A1 (ja) | 眼疾患治療剤 | |
| CN116474105A (zh) | 一种预防、缓解或治疗眼部疾病的药物组合物、制备方法及其应用 | |
| WO2024024920A1 (ja) | 眼科用組成物 |